Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients.

Bronte, G., Passiglia, F., Galvano, A., & Russo, A. (2016). Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?. EXPERT OPINION ON BIOLOGICAL THERAPY, 16(1), 1-5 [10.1517/14712598.2015.1075000].

Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?

Bronte, Giuseppe;Passiglia, Francesco;Galvano, Antonio;Russo, Antonio
2016

Abstract

Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients.
Bronte, G., Passiglia, F., Galvano, A., & Russo, A. (2016). Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?. EXPERT OPINION ON BIOLOGICAL THERAPY, 16(1), 1-5 [10.1517/14712598.2015.1075000].
File in questo prodotto:
File Dimensione Formato  
Expert Opinion on Biological Therapy Bronte Passiglia 2016.pdf

Solo gestori archvio

Dimensione 719.59 kB
Formato Adobe PDF
719.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/284245
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact